Sildenafil
Loading...Sildenafil Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Sildenafil tablets are indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in adults to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when sildenafil tablets were added to background epoprostenol therapy [see Clinical Studies (14)].
Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%).
Limitation of Use
The efficacy of sildenafil tablets in the treatment of pulmonary arterial hypertension (PAH) has not been adequately evaluated in patients taking bosentan.
History
There is currently no drug history available for this drug.
Other Information
Sildenafil citrate, USP, phosphodiesterase-5 (PDE-5) inhibitor, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type-5 (PDE-5). Sildenafil is also marketed as VIAGRA® for erectile dysfunction.
Sildenafil citrate, USP is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo [4,3-d] pyrimidin-5-yl)-4-ethoxyphenyl] sulfonyl]-4-methylpiperazine citrate and has the following structural formula:
Sildenafil citrate, USP is a white to off-white crystalline powder with a solubility of 3.5 mg/mL in water and a molecular weight of 666.7.
Sildenafil Tablets: Sildenafil tablets are formulated as white to off-white, round shaped film-coated tablets with 20 mg of sildenafil for oral administration. In addition to the active ingredient, sildenafil citrate, USP, each tablet contains the following inactive ingredients: croscarmellose sodium, dibasic calcium phosphate anhydrous, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
Sources
Sildenafil Manufacturers
-
Avpak
![Sildenafil (Sildenafil) Tablet [Avpak]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Sildenafil | Avpak
2.1 Sildenafil TabletsThe recommended dose of sildenafil tablets is 20 mg three times a day (TID). Administer sildenafil tablet doses 4 to 6 hours apart.
In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg TID is not recommended.
-
Auromedics Pharma Llc
Sildenafil | Walgreen Company
apply liberally before sun exposure and as needed
-
American Health Packaging
Sildenafil | American Health Packaging
2.1 Sildenafil TabletsThe recommended dose of sildenafil tablets is 20 mg three times a day. Administer sildenafil tablet doses 4 to 6 hours apart.
In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg three times a day is not recommended.
-
Northwind Pharmaceuticals, Llc
Sildenafil | Northwind Pharmaceuticals, Llc
The recommended dose of sildenafil tablets is 20 mg three times a day (TID). Administer sildenafil tablet doses 4-6 hours apart.
In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg TID is not recommended.
-
Greenstone Llc
Sildenafil | Teva Pharmaceuticals Usa Inc
Carvedilol tablets should be taken with food to slow the rate of absorption and reduce the incidence of orthostatic effects.
2.1 Heart FailureDOSAGE MUST BE INDIVIDUALIZED AND CLOSELY MONITORED BY A PHYSICIAN DURING UP-TITRATION. Prior to initiation of carvedilol tablets, it is recommended that fluid retention be minimized. The recommended starting dose of carvedilol tablets is 3.125 mg twice daily for 2 weeks. If tolerated, patients may have their dose increased to 6.25, 12.5, and 25 mg twice daily over successive intervals of at least 2 weeks. Patients should be maintained on lower doses if higher doses are not tolerated. A maximum dose of 50 mg twice daily has been administered to patients with mild-to-moderate heart failure weighing over 85 kg (187 lbs).
Patients should be advised that initiation of treatment and (to a lesser extent) dosage increases may be associated with transient symptoms of dizziness or lightheadedness (and rarely syncope) within the first hour after dosing. During these periods, patients should avoid situations such as driving or hazardous tasks, where symptoms could result in injury. Vasodilatory symptoms often do not require treatment, but it may be useful to separate the time of dosing of carvedilol tablets from that of the ACE inhibitor or to reduce temporarily the dose of the ACE inhibitor. The dose of carvedilol tablets should not be increased until symptoms of worsening heart failure or vasodilation have been stabilized.
Fluid retention (with or without transient worsening heart failure symptoms) should be treated by an increase in the dose of diuretics.
The dose of carvedilol tablets should be reduced if patients experience bradycardia (heart rate < 55 beats/minute).
Episodes of dizziness or fluid retention during initiation of carvedilol tablets can generally be managed without discontinuation of treatment and do not preclude subsequent successful titration of, or a favorable response to, carvedilol.
2.2 Left Ventricular Dysfunction Following Myocardial InfarctionDOSAGE MUST BE INDIVIDUALIZED AND MONITORED DURING UP-TITRATION. Treatment with carvedilol tablets may be started as an inpatient or outpatient and should be started after the patient is hemodynamically stable and fluid retention has been minimized. It is recommended that carvedilol tablets be started at 6.25 mg twice daily and increased after 3 to 10 days, based on tolerability, to 12.5 mg twice daily, then again to the target dose of 25 mg twice daily. A lower starting dose may be used (3.125 mg twice daily) and/or the rate of up-titration may be slowed if clinically indicated (e.g., due to low blood pressure or heart rate, or fluid retention). Patients should be maintained on lower doses if higher doses are not tolerated. The recommended dosing regimen need not be altered in patients who received treatment with an IV or oral β-blocker during the acute phase of the myocardial infarction.
2.3 HypertensionDOSAGE MUST BE INDIVIDUALIZED. The recommended starting dose of carvedilol tablets is 6.25 mg twice daily. If this dose is tolerated, using standing systolic pressure measured about 1 hour after dosing as a guide, the dose should be maintained for 7 to 14 days, and then increased to 12.5 mg twice daily if needed, based on trough blood pressure, again using standing systolic pressure one hour after dosing as a guide for tolerance. This dose should also be maintained for 7 to 14 days and can then be adjusted upward to 25 mg twice daily if tolerated and needed. The full antihypertensive effect of carvedilol tablets is seen within 7 to 14 days. Total daily dose should not exceed 50 mg.
Concomitant administration with a diuretic can be expected to produce additive effects and exaggerate the orthostatic component of carvedilol action.
2.4 Hepatic ImpairmentCarvedilol tablets should not be given to patients with severe hepatic impairment [see Contraindications (4)].
-
Dr. Reddy’s Laboratories Limited
Sildenafil | Dr. Reddy's Laboratories Limited
2.1 Sildenafil TabletsThe recommended dose of sildenafil tablets is 20 mg three times a day. Administer sildenafil doses 4 to 6 hours apart.
In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg three times a day is not recommended.
-
Northstar Rxllc
Sildenafil | Northstar Rxllc
2.1 Sildenafil TabletsThe recommended dose of sildenafil tablets is 20 mg three times a day. Administer sildenafil doses 4 to 6 hours apart.
In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg three times a day is not recommended.
-
Watson Laboratories, Inc.
Sildenafil | Actavis Pharma, Inc.
2.1 Sildenafil TabletsThe recommended dose of sildenafil tablets is 20 mg three times a day. Administer sildenafil doses 4 to 6 hours apart.
In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg three times a day is not recommended.
-
Mylan Pharmaceuticals Inc.
Sildenafil | Mylan Pharmaceuticals Inc.
2.1 Sildenafil TabletsThe recommended dose of sildenafil tablets is 20 mg three times a day (TID). Administer sildenafil tablet doses 4 to 6 hours apart.
In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg TID is not recommended.
-
Bryant Ranch Prepack
Sildenafil | Bryant Ranch Prepack
2.1 Sildenafil TabletsThe recommended dose of sildenafil tablets is 20 mg three times a day (TID). Administer sildenafil tablet doses 4 to 6 hours apart.
In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg TID is not recommended.
-
Amneal Pharmaceuticals, Llc
Sildenafil | Csl Behring Ag
For subcutaneous infusion only. Do not inject into a blood vessel.
2.1 Preparation and HandlingHizentra is a clear and pale yellow to light brown solution. Do not use if the solution is cloudy or contains particulates.
Prior to administration, visually inspect each vial of Hizentra for particulate matter or discoloration, whenever the solution and container permit. Do not freeze. Do not use any solution that has been frozen. Check the product expiration date on the vial label. Do not use beyond the expiration date. Do not mix Hizentra with other products. Do not shake the Hizentra vial. Use aseptic technique when preparing and administering Hizentra. The Hizentra vial is for single-use only. Discard all used administration supplies and any unused product immediately after each infusion in accordance with local requirements. 2.2 Dosage Hizentra can be administered at regular intervals from daily up to every two weeks (biweekly). Individualize the dose based on the patient's clinical response to Hizentra therapy and serum immunoglobulin G (IgG) trough levels. Before receiving treatment with Hizentra: Ensure that patients have received Immune Globulin Intravenous (Human) (IGIV) treatment at regular intervals for at least 3 months. Obtain the patient's serum IgG trough level to guide subsequent dose adjustments (see below under Dose Adjustment).Dosage for patients switching to Hizentra from Immune Globulin Intravenous (Human) (IGIV)
Establish the initial weekly dose of Hizentra by converting the monthly IGIV dose into a weekly equivalent and increasing it using a dose adjustment factor. The goal is to achieve a systemic serum IgG exposure (area under the concentration-time curve [AUC]) not inferior to that of the previous IGIV treatment. To calculate the initial weekly dose of Hizentra, divide the previous IGIV dose in grams by the number of weeks between doses during the patient's IGIV treatment (e.g., 3 or 4); then multiply this by the dose adjustment factor of 1.37. [see Pharmacokinetics (12.3, Table 8)] Initial Hizentra dose = Previous IGIV dose (in grams) × 1.37 Number of weeks between IGIV doses To convert the Hizentra dose (in grams) to milliliters (mL), multiply the calculated dose (in grams) by 5. Provided the total weekly dose is maintained, any dosing interval from daily up to biweekly can be used and will result in systemic serum IgG exposure that is comparable to the previous IGIV or weekly Hizentra treatment [see Pharmacokinetics (12.3)]. For biweekly dosing, multiply the calculated Hizentra weekly dose by 2. For frequent dosing (2 to 7 times per week), divide the calculated weekly dose by the desired number of times per week (e.g., for 3 times per week dosing, divide weekly dose by 3).Dosage for patients switching to Hizentra from IGSC
The previous weekly IGSC dose should be maintained. For biweekly dosing, multiply the previous weekly dose by 2. For frequent dosing (2 to 7 times per week), divide the previous weekly dose by the desired number of times per week (e.g., for 3 times per week dosing, divide weekly dose by 3).Start Hizentra treatment:
For weekly or frequent dosing, start treatment with Hizentra 1 week after the patient's last IGIV infusion or Hizentra/IGSC infusion. For biweekly dosing, start treatment 1 or 2 weeks after the last IGIV infusion or 1 week after the last weekly Hizentra/IGSC infusion.Dose Adjustment
Over time, the dose may need to be adjusted to achieve the desired clinical response and serum IgG trough level, irrespective of the frequency of administration. To determine if a dose adjustment should be considered, measure the patient's serum IgG trough level 2 to 3 months after switching to Hizentra.
Weekly dosing: When switching from IGIV to weekly Hizentra dosing, the target serum IgG trough level is projected to be approximately 16% higher than the last trough level during prior IGIV therapy [see Pharmacokinetics (12.3)].
Biweekly dosing: When switching from IGIV to biweekly Hizentra dosing, the target serum IgG trough level is projected to be approximately 10% higher than the last IGIV trough level. When switching from weekly to biweekly Hizentra dosing, the target trough is projected to be approximately 5% lower than the last trough level on weekly therapy [see Pharmacokinetics (12.3)].
Frequent dosing: When switching from weekly dosing to more frequent Hizentra dosing, the target serum IgG trough level is projected to be approximately 3 to 4% higher than the last trough level on weekly therapy [see Pharmacokinetics (12.3)].
To adjust the dose based on trough levels, calculate the difference (in mg/dL) between the patient's serum IgG trough level and the target IgG trough level for weekly or biweekly dosing. Then find this difference in Table 1 (Column 1) and, based on the Hizentra dosing frequency (for weekly or biweekly) and the patient's body weight, locate the corresponding adjustment amount (in mL) by which to increase (or decrease) the dose. For frequent dosing, add the weekly increment from Table 1 to the weekly-equivalent dose and then divide by the number of days of dosing.
Use the patient's clinical response as the primary consideration in dose adjustment. Additional dosage increments may be indicated based on the patient's clinical response (infection frequency and severity).
Table 1: Incremental Adjustment (mL)* of the Hizentra Dose† Based on the Difference (±mg/dL) from the Target Serum IgG Trough Level Difference From Target Serum IgG Trough Level (mg/dL) Dosing Frequency Weight Adjusted Dose Increment (mL)* Weight Group >10 to 30 kg >30 to 50 kg >50 to 70 kg >70 to 90 kg >90 kg n/a, not applicable. * Incremental adjustments based on slopes of the pharmacometric model-predicted relationship between serum IgG trough level and Hizentra dose increments of 1 mg/kg per week. † Includes biweekly, weekly or frequent dosing. ‡ To determine the dose increment for frequent dosing, add the weekly increment to the weekly-equivalent dose and then divide by the number of days of dosing. 50 Weekly‡ n/a 2.5 5 5 10 Biweekly 5 5 10 10 20 100 Weekly 2.5 5 10 10 15 Biweekly 5 10 20 20 30 200 Weekly 5 10 15 20 30 Biweekly 10 20 30 40 60For example, if a patient with a body weight of 70 kg has an actual IgG trough level of 900 mg/dL and the target trough level is 1000 mg/dL, this results in a difference of 100 mg/dL. Therefore, increase the weekly dose of Hizentra by 10 mL. For biweekly dosing, increase the biweekly dose by 20 mL. For 2 times per week dosing, increase the dose by 5 mL.
Monitor the patient's clinical response, and repeat the dose adjustment as needed.
Dosage requirements for patients switching to Hizentra from another IGSC product: If a patient on Hizentra does not maintain an adequate clinical response or a serum IgG trough level equivalent to that of the previous IGSC treatment, the physician may want to adjust the dose. For such patients, Table 1 also provides guidance for dose adjustment if their desired IGSC trough level is known.
Measles Exposure
Administer a minimum total weekly Hizentra dose of 200 mg/kg body weight for two consecutive weeks if a patient is at risk of measles exposure (i.e., due to an outbreak in the US or travel to endemic areas outside of the US. For biweekly dosing, one infusion of a minimum of 400 mg/kg is recommended. If a patient has been exposed to measles, ensure this minimum dose is administered as soon as possible after exposure.
2.3 AdministrationHizentra is for subcutaneous infusion only. Do not inject into a blood vessel.
Hizentra is intended for subcutaneous administration using an infusion pump. Infuse Hizentra in the abdomen, thigh, upper arm, and/or lateral hip.
Injection sites – A Hizentra dose may be infused into multiple injection sites. Use up to 4 sites simultaneously or up to 12 sites consecutively per infusion. Injection sites should be at least 2 inches apart. Change the actual site of injection with each administration. Volume – For the first infusion of Hizentra, do not exceed a volume of 15 mL per injection site. The volume may be increased to 20 mL per site for the fifth infusion and then to 25 mL per site as tolerated. Rate – For the first infusion of Hizentra, the recommended flow rate is 15 mL per hour per site. For subsequent infusions, the flow rate may be increased to 25 mL per hour per site as tolerated.Follow the steps below and use aseptic technique to administer Hizentra.
1. Assemble supplies – Gather the Hizentra vial(s), disposable supplies (not provided with Hizentra), and other items (infusion pump, sharps or other container, patient's treatment diary/log book) needed for the infusion. 2. Clean surface – Thoroughly clean a flat surface using an alcohol wipe. 3. Wash hands – Thoroughly wash and dry hands. The use of gloves when preparing and administering Hizentra is optional. 4. Check vials – Carefully inspect each vial of Hizentra. Do not use the vial if the liquid looks cloudy, contains particles, or has changed color, if the protective cap is missing, or if the expiration date on the label has passed. 5. Transfer Hizentra from vial(s) to syringe Remove the protective cap from the vial to expose the central portion of the rubber stopper of the Hizentra vial. Clean the stopper with an alcohol wipe and allow it to dry. If using a transfer device, follow the instructions provided by the device manufacturer. If using a needle and a syringe to transfer Hizentra, follow the instructions below. Attach a sterile transfer needle to a sterile syringe. Pull back on the plunger of the syringe to draw air into the syringe that is equal to the amount of Hizentra to be withdrawn. Insert the transfer needle into the center of the vial stopper and, to avoid foaming, inject the air into headspace of the vial (not into the liquid). Withdraw the desired volume of Hizentra.
When using multiple vials to achieve the desired dose, repeat this step. 6. Prepare infusion pump and tubing – Follow the manufacturer's instructions for preparing the pump, using subcutaneous administration sets and tubing, as needed. Be sure to prime the tubing with Hizentra to ensure that no air is left in the tubing.
7. Prepare injection site(s) The number and location of injection sites depends on the volume of the total dose. Infuse Hizentra into a maximum of 4 sites simultaneously; or up to 12 consecutively per infusion. Injection sites should be at least 2 inches apart. Using an antiseptic skin preparation, clean each site beginning at the center and working outward in a circular motion. Allow each site to dry before proceeding.
8. Insert needle(s) Grasp the skin between 2 fingers and insert the needle into the subcutaneous tissue. If necessary, use sterile gauze and tape or transparent dressing to hold the needle in place. Before starting the infusion, attach a sterile syringe to the end of the primed administration tubing and gently pull back on the plunger to make sure no blood is flowing back into the tubing. If blood is present, remove and discard the needle and tubing. Repeat the process beginning with step 6 (priming) using a new needle, new infusion tubing, and a different injection site. 9. Start infusion – Follow the manufacturer's instructions to turn on the infusion pump. 10. Record treatment – Remove the peel-off portion of the label from each vial used, and affix it to the patient's treatment diary/log book or scan the vial if recording the infusion electronically. 11. Clean up – After administration is complete, turn off the infusion pump. Take off the tape or dressing and remove the needle set from the infusion site(s). Disconnect the tubing from the pump. Immediately discard any unused product and all used disposable supplies in accordance with local requirements. Clean and store the pump according to the manufacturer's instructions.For self-administration, provide the patient with instructions and training for subcutaneous infusion in the home or other appropriate setting.
-
Remedyrepack Inc.
Sildenafil | Remedyrepack Inc.
The recommended dose of sildenafil is 20 mg three times a day (TID). Administer sildenafil doses 4 to 6 hours apart.
In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg TID is not recommended.
-
Remedyrepack Inc.
Sildenafil | Remedyrepack Inc.
The recommended dose of sildenafil is 20 mg three times a day (TID). Administer sildenafil doses 4 to 6 hours apart.
In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg TID is not recommended.
-
Avkare, Inc.
Sildenafil | Avkare, Inc.
2.1 Sildenafil TabletsThe recommended dose of sildenafil tablets is 20 mg three times a day (TID). Administer sildenafil tablet doses 4 to 6 hours apart.
In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg TID is not recommended.
-
Macleods Pharmaceuticals Limited
Sildenafil | Macleods Pharmaceuticals Limited
2.1 Sildenafil TabletsThe recommended dose of sildenafil tablets is 20 mg three times a day. Administer sildenafil tablets doses 4-6 hours apart.
In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg three times a day is not recommended.
-
Apotex Corp.
Sildenafil | Apotex Corp.
2.1 Sildenafil TabletsThe recommended dose of sildenafil tablets is 20 mg three times a day. Administer sildenafil tablet doses 4 to 6 hours apart.
In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg three times a day is not recommended.
-
Bluepoint Laboratories
Sildenafil | Bluepoint Laboratories
2.1 Sildenafil TabletsThe recommended dose of sildenafil tablets is 20 mg three times a day (TID). Administer sildenafil tablet doses 4 to 6 hours apart.
In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg TID is not recommended.
-
Teva Pharmaceuticals Usa Inc
Sildenafil | Supervalu Inc.
do not take more than directed (see overdose warning) adults and children 12 years and over
take 2 caplets every 4 hours swallow whole - do not crush, chew, or dissolve do not take more than 10 caplets in 24 hours children under 12 years: ask a doctor do not use more than directed (see overdose warning) adults and children 12 years and over:
take 2 caplets every 4 hours swallow whole - do not crush, chew, or dissolve do not take more than 10 caplets in 24 hours children under 12 years: ask a doctor -
Kaiser Foundation Hospitals
Sildenafil | Kaiser Foundation Hospitals
Sildenafil Tablets
The recommended dose of sildenafil is 20 mg three times a day. Administer sildenafil doses 4–6 hours apart.
In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg three times a day is not recommended.
-
Directrx
Sildenafil | Directrx
2.1 Sildenafil Tablets
The recommended dose of sildenafil tablets is 20 mg three times a day. Administer sildenafil tablets doses 4-6 hours apart.
In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg three times a day is not recommended.
![Sildenafil (Sildenafil Citrate) Injection, Solution [Auromedics Pharma Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e042ff45-6aa9-427c-8ab9-8fac3cff00ff&name=image-01.jpg)
![Sildenafil Tablet [American Health Packaging]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bec6f1c8-9dc8-48e6-b6fb-9a4eef7871f3&name=72c16ea3-5813-48db-bbbf-6602f4d6dcbb-08.jpg)
![Sildenafil Tablet, Film Coated [Northwind Pharmaceuticals, Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e06f3f68-3635-4fc0-b4d0-5ea46c0582ff&name=51655-131-20.jpg)
![Sildenafil (Sildenafil Citrate) Tablet, Film Coated [Greenstone Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=68c275e8-992a-4520-8065-ab6d615d89cc&name=image-06.jpg)
![Sildenafil (Sildenafil Citrate) Tablet, Film Coated [Northstar Rxllc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e4cd399a-7564-4b30-a4c5-0e554114b108&name=sildenafil-tablets---northstar-8.jpg)
![Sildenafil (Sildenafil Citrate) Tablet, Film Coated [Watson Laboratories, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f7455aa4-788e-40b9-9cde-afe92d170e8f&name=sildenafil-tablets-7.jpg)
![Sildenafil (Sildinafil) Tablet, Film Coated [Mylan Pharmaceuticals Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f7eec0c1-7054-44da-aa46-f3c33a939471&name=b4b88748-89a8-46ff-b00d-8ac5e4cb414f-08.jpg)
![Sildenafil Tablet [Bryant Ranch Prepack]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a636d3c7-af25-4148-8b4e-6f44deba700b&name=50291.jpg)
![Sildenafil Tablet [Amneal Pharmaceuticals, Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7b58f5ff-0316-49a3-b585-1f6003ddb953&name=igpro-20.jpg)
![Sildenafil (Sildenafil ) Tablet, Film Coated [Remedyrepack Inc. ]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dd566354-0da5-4259-8e10-9ded0eaaa1e1&name=MM8.jpg)
![Sildenafil (Sildenafil ) Tablet, Film Coated [Remedyrepack Inc. ]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0cd30ad7-1c4a-4c1e-aad3-a121119291c6&name=MM8.jpg)
![Sildenafil (Sildenafil) Tablet, Film Coated [Avkare, Inc.]](http://recallguide.cwdevelopsp.com/wp-content/themes/recallguide/assets/img/drug-image-placeholder.jpg)
![Sildenafil Tablet [Bluepoint Laboratories]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=72c16ea3-5813-48db-bbbf-6602f4d6dcbb&name=72c16ea3-5813-48db-bbbf-6602f4d6dcbb-08.jpg)
![Sildenafil Tablet, Film Coated [Teva Pharmaceuticals Usa Inc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b462a5d-d48b-4b73-b5d4-d7944730bbdd&name=equaline-44-470c473c-1.jpg)
![Sildenafil (Sildenafil Citrate) Tablet, Film Coated [Kaiser Foundation Hospitals]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=29afa2c7-6136-440d-9ae9-a95fa75aff75&name=sildenafil-10.jpg)
![Sildenafil Tablet, Film Coated [Directrx]](https://www.recallguide.org/wp-content/themes/bootstrap/assets/img/drug-image-placeholder.jpg)
Login To Your Free Account